• LAST PRICE
    0.4200
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.4010/ 1
  • Ask / Lots
    0.4200/ 7
  • Open / Previous Close
    0.0000 / 0.4200
  • Day Range
    ---
  • 52 Week Range
    Low 0.1590
    High 0.8900
  • Volume
    300
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 0.4644
TimeVolumeCELU
09:32 ET356170.443
09:33 ET3660.4299
09:35 ET527210.439
09:37 ET88730.4301
09:39 ET147350.443
09:42 ET325100.4301
09:44 ET12000.4351
09:46 ET15000.4302
09:48 ET1100.4301
09:50 ET65190.449
09:51 ET959190.449
09:53 ET1438850.46
09:55 ET32330.464
09:57 ET101750.46
10:00 ET668750.466
10:02 ET486000.46
10:06 ET185600.4649
10:11 ET4090.4696
10:15 ET61890.4528
10:20 ET24410.45
10:22 ET53000.4499
10:24 ET53890.45
10:26 ET5000.44
10:27 ET94750.4301
10:29 ET4150.4347
10:33 ET117430.4302
10:38 ET1000.4348
10:40 ET1000.43475
10:42 ET10000.4347
10:44 ET146000.4393
10:45 ET1000.4393
10:47 ET99040.43
10:51 ET50200.439
10:54 ET3000.431197
10:58 ET84630.43
11:00 ET24710.43
11:03 ET31480.43
11:05 ET96140.43
11:12 ET7350.4394
11:14 ET4730.4395
11:18 ET12270.4395
11:21 ET4200.431
11:25 ET36500.4307
11:30 ET99900.43
11:34 ET100000.43
11:36 ET102780.43
11:41 ET142290.43
11:45 ET334580.42
11:48 ET10000.4298
11:50 ET20000.4299
11:54 ET40000.4201
11:56 ET32710.42
11:59 ET112820.42
12:01 ET2000.4299
12:10 ET110000.4299
12:12 ET101000.4299
12:14 ET1450.42989
12:15 ET2430.424103
12:19 ET10000.429799
12:30 ET25400.4258
12:32 ET6960.4257
12:33 ET118090.42
12:35 ET41690.425799
12:39 ET50000.42
12:42 ET4600.4316
12:46 ET204330.42
12:48 ET15000.42
12:50 ET56590.4123
12:55 ET54290.412
01:00 ET2000.4121
01:04 ET30000.412
01:11 ET11440.412
01:13 ET43770.41
01:20 ET1650.4078
01:22 ET46120.4085
01:29 ET12000.4118
01:31 ET18000.41
01:33 ET2430.409
01:38 ET11900.407
01:47 ET25500.4101
01:49 ET10000.411
01:51 ET2270.4111
01:56 ET15000.4108
02:02 ET11030.41
02:03 ET35000.4066
02:05 ET2000.408
02:09 ET100000.41
02:18 ET46650.4101
02:23 ET6000.41
02:27 ET21000.40795
02:30 ET2000.409
02:32 ET7670.41
02:39 ET10000.41
02:41 ET10990.4084
02:43 ET229140.411961
02:45 ET55000.4119
02:48 ET151510.406535
02:50 ET20120.4069
02:52 ET102500.409851
02:59 ET6000.4084
03:01 ET54890.4068
03:03 ET23600.405
03:06 ET8580.406
03:08 ET360120.4061
03:10 ET127340.406
03:12 ET1000.40875
03:15 ET14970.4071
03:17 ET3180.41
03:19 ET1130.4119
03:24 ET5000.4119
03:26 ET268250.42
03:28 ET10280.42
03:30 ET10400.42
03:32 ET13000.4187
03:35 ET1000.42
03:37 ET41480.4223
03:39 ET4000.4235
03:42 ET1000.4241
03:44 ET3250.424
03:46 ET3700.4245
03:48 ET108390.4244
03:50 ET2000.4241
03:53 ET403090.4245
03:55 ET23000.4244
03:57 ET209910.4234
04:00 ET88350.42
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCELU
Celularity Inc
90.9M
-0.4x
---
United StatesIKNA
Ikena Oncology Inc
73.4M
-0.9x
---
United StatesLVTX
LAVA Therapeutics NV
55.7M
-1.1x
---
United StatesALGS
Aligos Therapeutics Inc
68.2M
-0.5x
---
United StatesICCC
ImmuCell Corp
40.1M
-6.4x
---
United StatesAADI
Aadi Bioscience Inc
48.6M
-0.8x
---
As of 2024-02-27

Company Information

Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), natural killer, cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CYCART-19, CYCART-201, CYNK-001, CYNK-301, CYNK-302, APPL-001, and pEXO-001. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the cluster of differentiation 19. pExo-001 is developed for the treatment of osteoarthritis. APPL-001 is developed for the treatment of Crohn’s disease.

Contact Information

Headquarters
170 Park AveFLORHAM PARK, NJ, United States 07932
Phone
908-768-2170
Fax
302-636-5454

Executives

Chairman of the Board, Chief Executive Officer
Robert Hariri
Chief Financial Officer
David Beers
President - Degenerative Disease
Stephen Brigido
Senior Executive Vice President, Chief Administrative Officer, General Manager
John Haines
Director
Shiu Fei Ling

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$90.9M
Revenue (TTM)
$14.8M
Shares Outstanding
216.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.28
EPS
$-1.05
Book Value
$1.34
P/E Ratio
-0.4x
Price/Sales (TTM)
6.1
Price/Cash Flow (TTM)
---
Operating Margin
-1,272.09%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.